Story
Alvotech Stock Jumps on Barclays Upgrade to Overweight Ahead of FDA Decisions
Summary
Alvotech (NASDAQ:ALVO) shares rose over 7% after Barclays upgraded the stock to Overweight and doubled its price target to $8.00, citing optimism for a positive FDA decision on three key biosimilars expected by December 4.
Shares of Alvotech (NASDAQ:ALVO) surged on Wednesday after Barclays upgraded the biotechnology company to Overweight, citing increased confidence in its ability to secure U.S. regulatory approval for three key biosimilar drug candidates later this year. The stock closed up 7.3% following the analyst note.
Barclays Lifts Rating
Barclays analyst Glen Santangelo raised the firm's rating on Alvotech to Overweight from a previous Underweight and doubled the price target to $8.00 per share from $4.00. The upgrade reflects a more positive outlook on the company's regulatory and manufacturing standing ahead of critical deadlines.
The firm's valuation model for the new price target assumes the successful U.S. approval of the three biologics. Barclays projects that this, combined with previously referenced milestone revenue, could drive adjusted EBITDA to a range of $270-290 million next year, justifying a 15-16x multiple.
FDA Decision Looms
The upgrade is primarily driven by an anticipated U.S. Food and Drug Administration (FDA) decision on December 4, 2026. Alvotech resubmitted its Biologics License Applications (BLAs) in June for its proposed biosimilars to several major drugs:
Ad- Simponi and Simponi Aria (AVT05)
- Eylea (AVT06)
- Prolia and Xgeva (AVT03)
The applications were refiled after the company previously received Complete Response Letters (CRLs) from the agency. The FDA has confirmed a standard six-month review process, making the December goal date a critical catalyst for the company.
Manufacturing and Financial Outlook
A key factor underpinning Barclays' optimism is the recent resolution of manufacturing concerns. The FDA completed a surveillance inspection of Alvotech’s Reykjavik facility in May and formally closed it in July with a 'Voluntary Action Indicated' classification. The company has stated the facility is back to full-scale manufacturing capacity.
Alvotech reaffirmed its fiscal 2026 revenue target of $650-700 million during its recent second-quarter report. The successful resolution of the facility inspection and potential approvals are seen as crucial steps toward achieving this financial guidance.
Read next
More on Stocks
ExxonMobil in Advanced Talks for Venezuela Return, Eyeing Former Orinoco Project
The U.S. oil major is reportedly negotiating a return to the Petromonagas heavy oil project, a significant reversal nearly two decades after its assets were nationalized by the Venezuelan government.
US House Passes Bill Targeting Data Center Power Grid Costs
The U.S. House of Representatives has advanced the Ratepayer Protection Act, the first legislation of its kind aimed at making large power users like data centers bear the costs of new electricity infrastructure.
New Zealand's Q2 GDP Growth Exceeds Forecasts but Remains Tepid at 0.2%
New Zealand's economy grew 0.2% in the second quarter, topping analyst and central bank forecasts, according to official data. However, the pace of expansion remains slow amid persistent economic headwinds and recent interest rate hikes.
Snap Partners With Salesforce, Nvidia to Target Enterprise Market With AR Glasses
Snap Inc. has announced strategic partnerships with Salesforce, Nvidia, and Amazon Web Services to integrate enterprise-grade AI and software tools into its Specs augmented-reality glasses, signaling a major push into the corporate market.